CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03344965
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:42.318069+00:00
Published At: 2026-01-05T00:00:00+00:00
Record Updated At: 2026-01-05
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Breast Cancer", "Invasive Breast Cancer", "Somatic Mutation Breast Cancer (BRCA1)", "Somatic Mutation Breast Cancer (BRCA2)", "CHEK2 Gene Mutation", "ATM Gene Mutation", "PALB2 Gene Mutation", "RAD51 Gene Mutation", "BRIP1 Gene Mutation", "NBN Gene Mutation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-05"
protocolSection.identificationModule.nctId: "NCT03344965"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.